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Abstract: We analyzed the PINK1 gene in 58 patients with
early-onset Parkinsonism and detected the homozygous
mutation W437X in 1 patient. The clinical phenotype was
characterized by early onset (22 years of age), good re-
sponse to levodopa, early ﬂuctuations and dyskinesias, and
psychiatric symptoms. The mother, heterozygote for
W437X mutation, was affected by Parkinson’s disease and
3 further relatives were reported affected, according to an
autosomal dominant transmission. © 2006 Movement Dis-
order Society
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Three autosomal recessive genes have been identiﬁed
to date as causative of early-onset Parkinsonism (EOP).
According to a referral based study, the Parkin gene
represents the most frequent cause of EOP, being respon-
sible for up to 50% of familial cases and 15% of sporadic
cases with onset younger than 45 years of age.1 Muta-
tions in the DJ-1 gene have a much lower prevalence, not
exceeding 1%.2 A third gene, PINK1, was found mutated
in several EOP families and further reports suggest a
1.5% to 2% prevalence in sporadic patients.3–9
In addition to the typical parkinsonian signs, EOP
patients present slow progression of the disease, excel-
lent response to levodopa, and early L-dopa–induced
ﬂuctuations and dyskinesias. Dementia and dysautono-
mia are rarely observed, whereas other atypical features
occasionally can be present. The range of Parkin pheno-
types is well known, because a large number of familial
and sporadic cases have been described to date.10–12
Conversely, only a limited number of patients with DJ-1
or PINK1 mutations have been reported, and the associ-
ated phenotypic spectrum still needs further deﬁnition.
We evaluated the presence of PINK1 mutations in a
cohort of 58 EOP cases from Southern Italy and describe
the phenotype of 2 patients from a family with appar-
ently dominant inheritance.
PATIENTS AND METHODS
Patients
After obtaining informed consent, 58 consecutive un-
related Italian patients (40 men, 18 women) with EOP
(onset  50 years of age) were recruited as inpatients or
outpatients at the Movement Disorder Clinic of the De-
partment of Neurology, Federico II University of Naples,
since June 2001. All patients originated from Southern
Italy, mostly from Campania. Diagnosis was made ac-
cording to the UK Brain Bank criteria for Parkinson’s
disease (PD), except the criterion that excludes familial
cases. Patients underwent a detailed neurological exam-
ination, including the Uniﬁed Parkinson’s Disease Rat-
ing Scale (UPDRS) and Hoehn & Yahr scale.
Mean age at onset  SD was 41.3  7.8 years (range,
20–49 years). A total of 34 patients were sporadic,
whereas 24 had at least 1 affected relative. An affected
ﬁrst-degree relative was reported in 15 cases (a parent in
9 and a sibling in 6). Parental consanguinity was reported
for 7 cases.
Molecular Analysis
Genomic DNA was isolated from peripheral blood
using standard techniques. PINK1 coding sequence was
ampliﬁed by polymerase chain reaction (PCR) and di-
rectly sequenced.4 When a homozygous mutation of
PINK1 was found in 1 patient, her parents were analyzed
by direct sequencing and by a quantitative PCR-based
exon dosage assay, to rule out heterozygous exon rear-
rangements.4 The presence of the mutation was excluded
in 50 healthy individuals from Campania.
RESULTS
Of 58 probands, 1 (1.7%) carried a homozygous
1311GA change in exon 7, resulting in the W437X
nonsense mutation. The patient’s mother and 3 other
relatives in the maternal line were reported to be affected
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by PD (Fig. 1). Both parents of the proband were clini-
cally examined and sampled, whereas the only affected
living relative (a proband’s cousin) refused to participate
in the study. The W437X mutation was detected in the
heterozygous state in both parents, who did not carry any
other pathogenic changes or gene rearrangements.
CASE REPORTS
Both parents of the proband originated from a small
village in Southern Italy, but consanguinity was denied.
The proband, a 51-year-old woman, ﬁrst noted bradyki-
nesia and tremor in the left leg at age 22. Over the next
year, symptoms spread to the left arm and subsequently
to the right side. Neither dystonia at onset nor sleep
beneﬁt were reported. L-Dopa was started approximately
1 year after disease onset, with marked clinical beneﬁt.
However, after approximately 2 years of L-dopa therapy,
wearing-off occurred leading to compulsive automedica-
tion (up to 2,000 mg daily) and painful leg dyskinesias.
At the same time, a depressive disorder with severe
histrionic and paranoid personality disturbances was di-
agnosed. Drug withdrawal at 48 years of age caused
severe off state (Hoehn & Yahr stage 5; UPDRS-III
score, 85). Apomorphine was added to L-dopa when she
was 50 years of age. On the last examination, she was
taking 100 mg of L-dopa and 1 mg of subcutaneous
apomorphine 10 times a day. In on state, very mild
bradykinesia and rigidity were observed (UPDRS-III
score, 8). After approximately 2 hours, the patient pro-
gressed to an on–off transition state characterized by
marked axial rigidity and bradykinesia, hypomimia, and
mild postural and action bilateral tremor (UPDRS-III
score, 44). Tendon reﬂexes were brisk. Dementia and
autonomic disturbances were absent. A brain magnetic
resonance imaging scan revealed slight supratentorial
and infratentorial atrophy. [123I]FP-CIT single-photon
emission computed tomography (SPECT) scan showed
that striatal DAT density was reduced by 62% in the
caudate and 76% in the putamen compared with average
control values. The right striatum was more affected,
with a posterior to anterior gradient of DAT decline.
The 73-year-old mother of the proband had onset at 53
years of age, with left arm rest tremor and bradykinesia.
L-Dopa was started from the beginning. On the last
examination, she was taking 800 mg of L-dopa daily with
good response, but motor ﬂuctuations, peak dyskinesias,
and early-morning dystonia were present. Examination
in off state revealed ﬂexed posture, mild postural insta-
bility, diffuse bradykinesia and rigidity prevalent on the
left side (Hoehn & Yahr stage III, UPDRS-III score: 42),
mild dyskinesias, and normal tendon reﬂexes. She re-
ported urinary urgency and was not demented. Neuro-
logical examination of the proband’s father at age 79 was
entirely normal. None of the subjects on the paternal line
was reported to be affected by PD. Both parents refused
to undergo further diagnostic procedures, such as
[123I]FP-CIT SPECT scanning. The 3 other affected rel-
atives of the family were reported by history to present
tremor, difﬁculties in gait, and slow movements.
DISCUSSION
We detected a homozygous mutation (W437X) in the
PINK1 gene in 1 of 58 EOP patients. The patient re-
ported here carries the same homozygous W437X as the
6 patients from the 2 Italian families originally linked to
PARK6.3 All these patients, including the present one,
share the same haplotype for markers surrounding the
gene (data not shown). Recently, W437X was found in
another Italian patient with EOP.13 Conversely, this mu-
tation was never identiﬁed in EOP patients of different
nationality,14 strongly suggesting a founder effect in It-
aly. The 7 previously described patients homozygote for
W437X presented a fairly typical parkinsonian pheno-
type, with asymmetric onset in the fourth or ﬁfth decade
(range, 30–48 years of age), wearing-off and L-dopa–
induced dyskinesias of variable severity, and absence of
psychiatric problems. The distinctive features in our pa-
tient are earlier age of onset (22 years) and presence of
major psychiatric disturbances. Cognitive or autonomic
abnormalities were absent in all W437X mutation carri-
ers, whereas dystonia at onset and diurnal ﬂuctuations
were rarely observed.
In the family reported here, both parents were het-
erozygous for the W437X mutation, but only the mother
was affected by PD. DNA from the remaining three
affected relatives was not available. An increasing num-
ber of patients carrying single heterozygous mutations in
one of the three EOP genes has been reported.1,2,4,7,9,11
The presence of a heterozygous mutation may be coin-
cidental to the disease, or alternatively a second mutation
FIG. 1. Pedigree of the family. Black symbols denote deﬁnitely af-
fected individuals, half-black symbols denote family members affected
by history. A diagonal slash across symbols indicates a deceased
individual. The arrow indicates the proband.
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(for instance, within regulatory untranslated regions)
may be missed, despite extensive screening. A third,
appealing hypothesis is that a single mutation could lead
to a nigrostriatal subclinical dopaminergic defect, which
would reach the threshold of disease only in the presence
of other genetic or environmental factors. The strongest
evidence in favor of this hypothesis comes from positron
emission tomographic studies, which concordantly dem-
onstrate a signiﬁcant decrease of 18F-dopa uptake in
Parkin and PINK1 heterozygous healthy carriers.15,16
Moreover, some heterozygous carriers present mild signs
of Parkinsonism, further supporting the existence of a
borderline dopaminergic dysfunction.
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Diffusion-Weighted Magnetic
Resonance Imaging in the
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Uremia
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Abstract: In this report, we have presented a diabetic pa-
tient with uremia, in which acute Parkinsonism occurred,
coupled with acute mental confusion, after a sudden in-
crease in blood urea nitrogen and serum creatinin levels.
Diffusion-weighted magnetic resonance imaging revealed a
unique cytotoxic-type edema in the bilateral basal ganglia
during the acute phase. Signal alterations were shown to
regress in accordance with the normalized apparent diffu-
sion coefﬁcient (ADC) values, but irreversible cystic degen-
eration developed in the globus pallidus, with the very low
preceding ADC values. © 2006 Movement Disorder Society
Key words: diffusion MRI; basal ganglia; diabetes mellitus;
uremia
The syndrome of acute bilateral basal ganglia lesions
in patients with diabetic uremia is a rare illness, which
normally affects Asian patients. Recently, several cases
of acute movement disorders with bilateral basal ganglia
involvement have been described in uremic–diabetic pa-
tients. This syndrome is characterized by reversible,
acute-onset Parkinsonism or dyskinesia, together with a
variety of symptoms, including disturbances of con-
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